These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22403424)

  • 1. Analysis of transmitted resistance to raltegravir and selective pressure among HIV-1-infected patients on a failing HAART in Sao Paulo, Brazil.
    Mantovani NP; Azevedo RG; Rabelato JT; Sanabani S; Diaz RS; Komninakis SV
    J Clin Microbiol; 2012 Jun; 50(6):2122-5. PubMed ID: 22403424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polymorphisms of HIV-2 integrase and selection of resistance to raltegravir.
    Bercoff DP; Triqueneaux P; Lambert C; Oumar AA; Ternes AM; Dao S; Goubau P; Schmit JC; Ruelle J
    Retrovirology; 2010 Nov; 7():98. PubMed ID: 21114823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
    Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
    Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Substitutions at amino acid positions 143, 148, and 155 of HIV-1 integrase define distinct genetic barriers to raltegravir resistance in vivo.
    Fransen S; Gupta S; Frantzell A; Petropoulos CJ; Huang W
    J Virol; 2012 Jul; 86(13):7249-55. PubMed ID: 22553340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
    Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In-vivo selection of the mutation F121Y in a patient failing raltegravir containing salvage regimen.
    Souza Cavalcanti J; Minhoto Lança A; de Paula Ferreira JL; da Eira M; de Souza Dantas DS; de Macedo Brígido LF
    Antiviral Res; 2012 Jul; 95(1):9-11. PubMed ID: 22564967
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-1 integrase inhibitor resistance and its clinical implications.
    Blanco JL; Varghese V; Rhee SY; Gatell JM; Shafer RW
    J Infect Dis; 2011 May; 203(9):1204-14. PubMed ID: 21459813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV-1-infected patients with advanced disease failing a raltegravir-containing salvage regimen in São Paulo, Brazil.
    de Souza Cavalcanti J; de Paula Ferreira JL; Vidal JE; de Souza Guimarães PM; Moreira DH; de Macedo Brigido LF;
    Int J Antimicrob Agents; 2014 Mar; 43(3):287-91. PubMed ID: 24359837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation Q95K enhances N155H-mediated integrase inhibitor resistance and improves viral replication capacity.
    Fun A; Van Baelen K; van Lelyveld SF; Schipper PJ; Stuyver LJ; Wensing AM; Nijhuis M
    J Antimicrob Chemother; 2010 Nov; 65(11):2300-4. PubMed ID: 20736234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring the emergence of resistance mutations in patients infected with HIV-1 under salvage therapy with raltegravir in Rio de Janeiro, Brazil: a follow-up study.
    Passaes CP; Guimarães ML; Cardoso SW; Pilotto JH; Veloso V; Grinsztejn B; Morgado MG
    J Med Virol; 2012 Dec; 84(12):1869-75. PubMed ID: 23080489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir.
    Canducci F; Ceresola ER; Saita D; Castagna A; Gianotti N; Underwood M; Burioni R; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2013 Nov; 68(11):2525-32. PubMed ID: 23798668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    Alessandri-Gradt E; Morgand M; Delaugerre C; Peytavin G; Sellier P; Simon F; Plantier JC
    AIDS; 2015 Jun; 29(10):1271-3. PubMed ID: 26035328
    [No Abstract]   [Full Text] [Related]  

  • 13. Resistance to raltegravir highlights integrase mutations at codon 148 in conferring cross-resistance to a second-generation HIV-1 integrase inhibitor.
    Goethals O; Van Ginderen M; Vos A; Cummings MD; Van Der Borght K; Van Wesenbeeck L; Feyaerts M; Verheyen A; Smits V; Van Loock M; Hertogs K; Schols D; Clayton RF
    Antiviral Res; 2011 Aug; 91(2):167-76. PubMed ID: 21669228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergence of raltegravir-resistant HIV-1 in the central nervous system.
    Watanabe K; Honda M; Watanabe T; Tsukada K; Teruya K; Kikuchi Y; Oka S; Gatanaga H
    Int J STD AIDS; 2010 Dec; 21(12):840-1. PubMed ID: 21297097
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 resistance patterns to integrase inhibitors in antiretroviral-experienced patients with virological failure on raltegravir-containing regimens.
    da Silva D; Van Wesenbeeck L; Breilh D; Reigadas S; Anies G; Van Baelen K; Morlat P; Neau D; Dupon M; Wittkop L; Fleury H; Masquelier B
    J Antimicrob Chemother; 2010 Jun; 65(6):1262-9. PubMed ID: 20388636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
    Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
    J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.
    Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M
    Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimal sequence variability of the region of HIV-1 integrase targeted by the Abbott RealTime HIV-1 viral load assay in clinical specimens with reduced susceptibility to raltegravir.
    Young TP; Napolitano LA; Paquet AC; Parkin NT; Fransen S; Trinh R; Haddad M; Hackett J; Cloherty GA
    J Virol Methods; 2013 Nov; 193(2):693-6. PubMed ID: 23892128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study.
    Eron JJ; Clotet B; Durant J; Katlama C; Kumar P; Lazzarin A; Poizot-Martin I; Richmond G; Soriano V; Ait-Khaled M; Fujiwara T; Huang J; Min S; Vavro C; Yeo J;
    J Infect Dis; 2013 Mar; 207(5):740-8. PubMed ID: 23225901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
    Ghosn J; Mazet AA; Avettand-Fenoel V; Peytavin G; Wirden M; Delfraissy JF; Chaix ML
    J Antimicrob Chemother; 2009 Aug; 64(2):433-4. PubMed ID: 19457931
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.